

## Special Issue

# Clinical Applications of Molecular Subtyping of Pancreatic Cancer

### Message from the Guest Editor

This Special Issue is dedicated to publishing research centered around the developments in molecular subtyping of pancreatic cancer, whether related to a novel method, a transcriptomic subtype method or single gene alteration. In this Special Issue, original research articles, reviews are welcome. Research areas may include (but are not limited to) the following:

- Implications of pancreatic molecular cancer in pancreatic surgery;
- Association of postoperative outcomes in different molecular subtypes;
- Response to systematic therapy according to molecular subtypes;
- Implications of pancreatic transplant in genomic changes;
- Use of NGS in pancreatic cancer specimens;
- Personalized decision-making based on molecular subtyping;
- New advancements in targeted treatment strategies.

We look forward to receiving your contributions.

---

### Guest Editor

Dr. Ioannis C. Maroulis

Department of Surgery, University of Patras Medical School, 26500 Patras, Greece

---

### Deadline for manuscript submissions

closed (1 July 2024)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/183711](https://mdpi.com/si/183711)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)